Document is current
Any future updates will be listed below
-
Authors
Kjellberg, Anders https://orcid.org/0000-0002-4819-1024
Hassler, Adrian https://orcid.org/0000-0002-5796-1801
Boström, Emil https://orcid.org/0000-0001-6922-7631
El Gharbi, Sara https://orcid.org/0000-0002-0632-1839
Al-Ezerjawi, Sarah https://orcid.org/0000-0002-5940-6182
Kowalski, Jan https://orcid.org/0000-0001-5414-6556
Rodriguez-Wallberg, Kenny A. https://orcid.org/0000-0003-4378-6181
Bruchfeld, Judith https://orcid.org/0000-0001-5399-0982
Ståhlberg, Marcus https://orcid.org/0000-0003-0319-6240
Nygren-Bonnier, Malin https://orcid.org/0000-0001-6731-8468
Runold, Michael https://orcid.org/0000-0001-7568-2278
Lindholm, Peter https://orcid.org/0000-0002-0840-9244
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04842448 at ClinicalTrials.govDocuments that mention this clinical trial
Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial
https://doi.org/10.1186/s12879-023-08002-8
Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial
https://doi.org/10.1136/bmjopen-2024-094386
Long covid—mechanisms, risk factors, and management
https://doi.org/10.1136/bmj.n1648
Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial
https://doi.org/10.1136/bmjopen-2022-061870
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden
Stockholms Läns Landsting
Oura Oy
Karolinska Institute
- License Information
-
More Information
Article History
Received: 12 July 2022
Accepted: 10 January 2023
First Online: 20 January 2023
Declarations
:
: The trial is conducted in accordance with The Declaration of Helsinki, ICH-GCP, local and national regulations. The trial was approved by The Swedish ethical review board (EPM no 2021-02634, amendment 2021-04572), approval 2021-05-25 and 2021-09-22 and The Swedish medical products agency (LV no 5.1-2020-36673), approval 2021-07-06. The trial was registered online (NCT04842448) and EudraCT number: 2021-000764-30 before start of the trial.
: All subjects have signed an informed consent form compliant with ICH-GCP, including information of dissemination and data sharing.
: AK and PL disclose funding from Swedish Heart–Lung foundation, Stockholm Council and Oura Health Oy for the current trial. MS discloses funding from Swedish Research Council and Dysautonomia International during the trial and previously from HLF. MS also disclose consulting fee from Swedish agency for health technology assessment of social services, speaker honoraria from Orion Pharma, Werfen and has filed a patent for pharmacological treatment in post-COVID POTS. JK disclose consulting fee for statistical work in this trial. AH, EB, SEG, SAE, JK, JB, MNB, MR declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
